---
title: 二芳基乙胺类物质
description: 
published: true
date: 2026-01-30T10:34:51.594Z
tags: 
editor: markdown
dateCreated: 2026-01-30T06:15:20.395Z
---

[◀返回](./home.md)

# 二芳基乙胺类物质 (Diarylethylamines)

<mark> 嗯，不错<mark>

| ![Songbird-egg.svg](../../文件/Songbird-egg.svg) | **本文是一个[小作品](../../关于本站/关于FreeODwiki.md "Stub")。**<br>*因此，它可能包含不完整或错误的信息。您可以帮忙[扩充它](https://psychonautwiki.org/w/index.php?title=Diarylethylamines&action=edit)。* |
| --- | --- |

[![](../../文件/Substituted_diarylethylamine.svg)](../../文件/Substituted_diarylethylamine.svg)

[![](../../文件/Substituted_diarylethylamine.svg "Enlarge")](../../文件/Substituted_diarylethylamine.svg)

二芳基乙胺的一般化学结构

**二芳基乙胺类物质（Diarylethylamines）** 是一类[精神活性物质](./home.md "Psychoactive substances")，在[给药](./文档/给药途径.md "Administered")后会产生[解离](../解离剂.md "Dissociative")效应。[主观效应](../科学信息索引页.md "Subjective effects")与[PCP](../../药物/PCP.md "PCP")或[氯胺酮](../../药物/氯胺酮.md "Ketamine")等[芳基环己胺类](./芳基环己胺类物质.md "Arylcyclohexylamine")解离剂相似，尽管它们的化学结构不同。

二芳基乙胺类物质是当代[策划药](../研究用化学品.md)的例子，被专门选择用来模仿和/或替代常用非法物质的功能和结构特征。它们作为[MXE](../../药物/MXE.md "MXE")和其他解离剂的替代品在在线研究用化学品市场上销售。

关于这些化合物的人体药理学、代谢和毒性知之甚少。许多报告表明，它们可能带来与传统解离剂不同且更显著的风险。

内容
--------

* [1 药理学](#药理学)
* [2 取代二芳基乙胺类物质列表](#取代二芳基乙胺类物质列表)
* [3 另见](#另见)
* [4 文献](#文献)
* [5 参考资料](#参考资料)

### 药理学

*五种目标1,2-二苯乙胺及参考化合物的NMDAR结合亲和力[\[1\]](#cite_note-Pharma2016-1)*

| 化合物 | IC50 ± SEM (nM) | Ki ± SEM (nM) |
| --- | --- | --- |
| [PCP](../../药物/PCP.md "PCP")[\[2\]](#cite_note-2) | 91 ± 1.3 | 57.9 ± 0.8 |
| [氯胺酮](../../药物/氯胺酮.md "Ketamine") | 508.5 ± 30.1 | 323.9 ± 19.2 |
| [美金刚](../../药物/美金刚.md "Memantine") | 594.2 ± 41.3 | 378.4 ± 26.3 |
| (+)-[MK-801](../../药物/MK-801.md "MK-801 (page does not exist)") | 4.1 ± 1.6 | 2.5 ± 1.0 |
| [Diphenidine](../../药物/DPD.md "Diphenidine")\* | 28.6 ± 3.5 | 18.2 ± 2.2 |
| 2-MXP ([Methoxphenidine](../../药物/Methoxphenidine.md "Methoxphenidine")) | 56.5 ± 5.8 | 36.0 ± 3.7 |
| 3-MXP | 30.3 ± 2.6 | 19.3 ± 1.7 |
| 4-MXP | 723.8 ± 69.9 | 461.0 ± 44.5 |
| 2-Cl-Diphenidine\* | 14.6 ± 2.1 | 9.3 ± 1.3 |

*注：NMDAR结合亲和力是在大鼠前脑中使用 \[3H\]-(+)-MK-801 测定的。[\[1\]](#cite_note-Pharma2016-1)<br>\*Diphenidine 在科学研究中有时被称为 DPH，尽管该名称已通用并广泛被认为是[苯海拉明](../../药物/苯海拉明.md "Diphenhydramine")（一种无关物质）的缩写。*

*1,2-二芳基乙胺作为单胺转运体再摄取抑制剂的抑制效力。[\[1\]](#cite_note-Pharma2016-1)*

| 化合物 | DAT (IC50 ± SEM, μM) | NET (IC50 ± SEM, μM) | SERT (IC50 ± SEM, μM) |
| --- | --- | --- | --- |
| DPH ([Diphenidine](../../药物/DPD.md "Diphenidine")) | 1.99 (0.91) | 9.25 (0.97) | >10 μM |
| 2-MXP ([Methoxphenidine](../../药物/Methoxphenidine.md "Methoxphenidine")) | 30.0 (0.81) | 35.2 (2.04) | >10 μM |
| [3-MXP](../../药物/3-MXP.md "3-MXP (page does not exist)") | 0.587 (0.92) | 2.71 (0.95) | >10 μM |
| [4-MXP](../../药物/4-MXP.md "4-MXP (page does not exist)") | 2.23 (0.96) | 22.5 (1.75) | 19.0 (1.12) |
| [2-Cl-DPH](../../药物/2-Cl-DPH.md "2-Cl-DPH (page does not exist)") | 10.5 (0.65) | 27.1 (1.02) | >10 μM |

*注：IC50值以μM显示。希尔斜率显示在括号中。ND-IC50值未测定，因为化合物在初步筛选期间在10 μM时表现出低于50%的摄取抑制。<br>1,2-二芳基乙胺作为单胺转运体再摄取抑制剂的抑制效力。[\[1\]](#cite_note-Pharma2016-1)*


取代二芳基乙胺类物质列表
-------------------------------------

| **化合物** | **RN1** | **RN2** | **R2** | **结构** |
| --- | --- | --- | --- | --- |
| [Ephenidine](../../药物/EPH.md "Ephenidine") | CH2CH3 | H | H | [![Ephenidine.svg](../../文件/Ephenidine.svg)](../../文件/Ephenidine.svg) |
| [Diphenidine](../../药物/DPD.md "Diphenidine") | CH2CH2CH2- | CH2CH2- | H | [![Diphenidine.svg](../../文件/Diphenidine.svg)](../../文件/Diphenidine.svg) |
| [Methoxphenidine](../../药物/Methoxphenidine.md "Methoxphenidine") | CH2CH2CH2- | CH2CH2- | OCH3 | [![Methoxphenidine.svg](../../文件/Methoxphenidine.svg)](../../文件/Methoxphenidine.svg) |


另见
--------

* [负责任的用药索引页](../负责任的用药索引页.md "Responsible use")
* [解离剂](./解离剂.md "Dissociative")
* [芳基环己胺类物质](./芳基环己胺类物质.md "Arylcyclohexylamine")


文献
----------

* Wallach, J., Kang, H., Colestock, T., Morris, H., Bortolotto, Z. A., Collingridge, G. L., ... & Adejare, A. (2016). Pharmacological investigations of the dissociative ‘legal highs’ diphenidine, methoxphenidine and analogues. PLoS One, 11(6), e0157021. <https://doi.org/10.1371/journal.pone.0157021>
* Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6(7–8), 614–632. <https://doi.org/10.1002/dta.1620>
* Wallach, J., & Brandt, S. D. (2018). 1, 2-Diarylethylamine-and Ketamine-Based New Psychoactive Substances. In New Psychoactive Substances (pp. 305-352). Springer, Cham. <http://dx.doi.org/10.1007/164_2018_148>


参考资料
----------

1. ↑ [1.0](#cite_ref-Pharma2016_1-0) [1.1](#cite_ref-Pharma2016_1-1) [1.2](#cite_ref-Pharma2016_1-2) [1.3](#cite_ref-Pharma2016_1-3) ["Pharmacological Investigations of the Dissociative 'Legal Highs' Diphenidine, Methoxphenidine and Analogues"](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0157021). *PLOS ONE*. **11** (6): e0157021. 17 June 2016. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1371/journal.pone.0157021](//doi.org/10.1371%2Fjournal.pone.0157021). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [1932-6203](//www.worldcat.org/issn/1932-6203).
2. [↑](#cite_ref-2) Wallach, J. (2014). ["Structure activity relationship (SAR) studies of arylcycloalkylamines as N-methyl-D-aspartate receptor antagonists"](https://www.semanticscholar.org/paper/Structure-activity-relationship-(SAR)-studies-of-as-Wallach/cc0f16999e363db74bd501f5a041083f6b0f6b5a). *UNIVERSITY OF THE SCIENCES IN PHILADELPHIA*: 626.